Juntasopeepun Phanida, Davidson Patricia M, Srisomboon Jatupol
Faculty of Nursing, Chiang Mai University, Chiang Mai, Thailand.
Collegian. 2012;19(1):45-50. doi: 10.1016/j.colegn.2011.08.002.
The discovery of the HPV vaccine has been a major breakthrough in preventing cervical cancer and other HPV-related diseases around the globe. Cervical cancer is a significant public health problem in Thailand. Despite the long-time availability of cervical cancer screening programs in Thailand, the uptake among the target female population remains low. HPV vaccines were approved by the Food and Drug Administration of Thailand in 2007. As of March 2011, due to financial limitations, HPV vaccines have still not been included in the national immunization program under the public health benefit plans although individuals has the option to pay privately for the vaccine. This paper discusses the issues and challenges in implementing cervical cancer screening programs in the era of HPV vaccination in Thailand. Recommendations to increase the uptake of cervical cancer screening and further research to inform a policy regarding the cervical cancer screening measures are proposed.
人乳头瘤病毒(HPV)疫苗的发现是全球预防宫颈癌及其他HPV相关疾病的一项重大突破。宫颈癌在泰国是一个严重的公共卫生问题。尽管泰国长期开展宫颈癌筛查项目,但目标女性人群的参与率仍然很低。HPV疫苗于2007年获得泰国食品药品管理局批准。截至2011年3月,由于资金限制,HPV疫苗仍未被纳入公共卫生福利计划下的国家免疫规划,不过个人可以选择自费接种该疫苗。本文讨论了泰国在HPV疫苗接种时代实施宫颈癌筛查项目的问题与挑战。文中还提出了提高宫颈癌筛查参与率的建议以及为宫颈癌筛查措施相关政策提供依据的进一步研究方向。